Aerovate Therapeutics, (id:6552 AVTE)
2.66 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 8:22:01 PM)
Exchange closed, opens in 1 day 13 hours
1.92 USD (1.92%)
2.11 USD (2.11%)
26.07 USD (26.07%)
-84.76 USD (-84.76%)
-83.04 USD (-83.04%)
-90.50 USD (-90.50%)
About Aerovate Therapeutics,
Market Capitalization 76.81M
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
| Headquarters (address) |
930 Winter Street Waltham 02451 MA United States |
| Phone | 617 443 2400 |
| Website | https://aerovatetx.com |
| Employees | 51 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | AVTE |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 1.25 - 32.42 |
| Market Capitalization | 76.81M |
| P/E trailing | -0.927 |
| P/E forward | -2.66 |
| Price/Book | 0.954 |
| Beta | 0.999 |
| EPS | -2.99 |
| EPS United States (ID:6, base:3403) | 24.22 |